- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01536886
LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris
August 9, 2016 updated by: LEO Pharma
A Phase 2 Study Comparing Treatment With LEO 90100 With Calcipotriol Plus Betamethasone Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris.
The purpose of this study is to investigate whether LEO 90100 and calcipotriol plus betamethasone are effective in the treatment of psoriasis vulgaris.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
376
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arkansas
-
Hot Springs, Arkansas, United States, 71913
- Burke Pharmaceutical Research
-
-
California
-
Los Angeles, California, United States, 90045
- Dermatology Research Associates
-
Oceanside, California, United States, 92056
- Dermatology Specialists, Inc.
-
San Diego, California, United States, 92123
- University Clinical Trials, Inc.
-
San Diego, California, United States, 92117
- Skin Surgery Medical Group, Inc
-
Santa Monica, California, United States, 90404
- Clinical Science Institute
-
-
Colorado
-
Denver, Colorado, United States, 80220
- Horizons Clinical Research Center
-
Denver, Colorado, United States, 80210
- Colorado Medical Research Center, Inc
-
Denver, Colorado, United States, 80113
- About Skin Dermatology and DermSurgery, PC
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- Dermatology Associates and Research
-
Jacksonville, Florida, United States, 32204
- North Florida Dermatology Associates, PA
-
Miami, Florida, United States, 33144
- International Dermatology Research, Inc.
-
Ormond Beach, Florida, United States, 32174
- Ameriderm Research
-
-
Georgia
-
Snellville, Georgia, United States, 30078
- Gwinnett Clinical Research Ctr, Inc
-
-
Illinois
-
Arlington Heights, Illinois, United States, 60005
- Altman Dermatology Associates
-
Buffalo Grove, Illinois, United States, 60089
- Glazer Dermatology
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Clinical Research Advantage, Inc./Hudson Dermatology, LLC
-
Indianapolis, Indiana, United States, 46256
- Dawes Fretzin Clinical Research Group
-
Plainfield, Indiana, United States, 46168
- The Indiana Clinical Trials Center
-
-
Kentucky
-
Owensboro, Kentucky, United States, 42303
- Owensboro Dermatology Associates
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48103
- David Fivenson, MD, PLC
-
Bay City, Michigan, United States, 48706
- Great Lakes Research Group, Inc.
-
Troy, Michigan, United States, 48084
- Derm Center
-
Warren, Michigan, United States, 48008
- Grekin Skin Institute
-
-
Minnesota
-
Fridley, Minnesota, United States, 55432
- Minnesota Clinical Study Center
-
-
New Jersey
-
East Windsor, New Jersey, United States, 08520
- Psoriasis Treatment Center of Central NJ
-
Verona, New Jersey, United States, 07044
- The Dermatology Group, PC
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106-5239
- Academic Dermatology Associates
-
-
New York
-
Stony Brook, New York, United States, 11790
- Derm Research Center of New York
-
-
Pennsylvania
-
Fort Washington, Pennsylvania, United States, 19034
- Philadelphia Institute of Dermatology
-
-
Texas
-
Dallas, Texas, United States, 75246
- Menter Dermatology Research Institute
-
Houston, Texas, United States, 77056
- Suzanne Bruce and Associates, P.A.,The Center for Skin Research
-
Houston, Texas, United States, 77065
- Center for Clinical Studies
-
San Antonio, Texas, United States, 78229
- Progressive Clinical Research
-
San Antonio, Texas, United States, 78229
- Dermatology Clinical Research Center of San Antonio
-
San Antonio, Texas, United States, 78229
- Clinical Trials of Texas, Inc
-
-
Utah
-
Salt Lake City, Utah, United States, 84117
- Dermatology Research Center, Inc.
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Virginia Clinical Research, Inc.
-
-
Washington
-
Spokane, Washington, United States, 99204
- Premier Clinical Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed and dated informed consent obtained prior to any trial related activities (including washout period).
- Age 18 years or above
- Either sex
- Any race or ethnicity
- All skin types
- Females of childbearing potential must have a negative pregnancy test at Day 0 (Visit 1).
- Females of childbearing potential must agree to use a highly effective method of birth control during the study. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year).
- Able to communicate with the investigator and understand and comply with the requirements of the study.
Exclusion Criteria:
Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:
- etanercept - within 4 weeks prior to randomisation
- adalimumab, alefacept, infliximab - within 8 weeks prior to randomisation
- ustekinumab - within 16 weeks prior to randomisation
- other products - 4 weeks/5 half-lives (whichever is longer)
- Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants) within 4 weeks prior to randomisation.
- Subjects who have received treatment with any nonmarketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.
- PUVA therapy within 4 weeks prior to randomisation.
- UVB therapy within 2 weeks prior to randomisation.
- Planned excessive exposure of area(s) to be treated with study medication to either natural or artificial sunlight (including tanning booths, sun lamps, etc.) during the study.
- Planned initiation of, or changes to, concomitant medication that could affect psoriasis vulgaris (e.g. beta blockers, antimalarial drugs, lithium, ACE inhibitors) during the study.
- Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis.
- Subjects with any of the following conditions present on the treatment area: viral (e.g. herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, icthyosis, ulcers and wounds.
- Other inflammatory skin disorders (e.g. seborrhoeic dermatitis or contact dermatitis) on the treatment area that may confound the evaluation of psoriasis vulgaris.
- Known or suspected disorders of calcium metabolism associated with hypercalcaemia.
- Known or suspected severe renal insufficiency or severe hepatic disorders.
- Known or suspected hypersensitivity to component(s) of the investigational products.
- Current participation in any other interventional clinical study.
- Previously randomised in this study.
- Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: LEO 90100 vehicle
Aerosol foam with no active ingredient
|
|
ACTIVE_COMPARATOR: Betamethasone plus calcipotriol
Calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) ointment
|
|
EXPERIMENTAL: LEO 90100
LEO 90100 aerosol foam: calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)
|
|
PLACEBO_COMPARATOR: Ointment vehicle
Ointment with no active ingredients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects With 'Controlled Disease' ('Clear'/'Almost Clear' for Subjects w. at Least Moderate Disease at Baseline, 'Clear' for Subjects With Mild Disease at Baseline) According to the Investigator's Global Assessment (IGA) on the Trunk and Limbs at Week 4.
Time Frame: 4 weeks
|
Assessment of disease severity (Plaque thickening, Scaling and Erythema) using a 5-point scale (Clear, Almost clear, Mild, Moderate, Severe), based on the condition of the disease at the time of evaluation.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Koo, MD, University of California, San Francisco School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, Bagel J. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. J Dermatolog Treat. 2016;27(2):120-7. doi: 10.3109/09546634.2015.1083935. Epub 2015 Oct 7.
- Iversen L, Kurvits M, Snel-Prento AM, Menter A. Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA >/= 3: Post-Hoc Analysis From Three Randomized Controlled Trials. Dermatol Ther (Heidelb). 2020 Oct;10(5):1111-1120. doi: 10.1007/s13555-020-00419-2. Epub 2020 Aug 12.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (ACTUAL)
September 1, 2012
Study Completion (ACTUAL)
November 1, 2012
Study Registration Dates
First Submitted
February 16, 2012
First Submitted That Met QC Criteria
February 21, 2012
First Posted (ESTIMATE)
February 22, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
September 19, 2016
Last Update Submitted That Met QC Criteria
August 9, 2016
Last Verified
August 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LEO 90100-35
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
University of California, San FranciscoTerminatedPlaque Psoriasis | Psoriasis VulgarisUnited States
-
University Hospital, GhentBelgium Health Care Knowledge CentreNot yet recruiting
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
Clinical Trials on LEO 90100
-
LEO PharmaCompletedPsoriasis VulgarisUnited States, Canada, Germany, United Kingdom, France, Poland
-
LEO PharmaCompleted
-
LEO PharmaCompletedPsoriasis VulgarisUnited States, Netherlands, Poland, Romania
-
LEO PharmaCompletedPsoriasis VulgarisFrance
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
LEO PharmaCompleted
-
LEO PharmaCompletedSkin and Connective Tissue DiseasesFrance